Infectious Disease Frontier Archives - Page 9 of 37

Dr. Yonghong Xiao: From Concept to Action, Implementing One Health Strategies and Multidisciplinary Cooperation | Chairperson Interview

By Peng Longmei 2024.10.21

Editor’s Note: Antimicrobial resistance (AMR) continues to challenge global public health, demanding human ingenuity and collaboration. The One Health concept has emerged as a key strategy to curb AMR. Recently,…

ESCMID-EUCIC | Guidelines on Preoperative Decolonization and Targeted Prevention for MDR Gram-Positive Bacteria

By Siqi Wang 2024.10.20

Editorial Note: Surgical site infections (SSIs) are among the most common postoperative complications, not only prolonging hospital stays and increasing medical costs but also severely impacting patient survival and quality…

Non-KPC Characteristics of Novel BL/BLI Compounds in Pseudomonas aeruginosa

By Mourabit Halima 2024.10.17

Editor's Note: In the previous article, we provided a detailed overview of the advancements in the use of novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations in Enterobacterales with various resistance mechanisms. This…

New Characteristics of BL/BLI Compounds Targeting Non-KPC Enterobacterales

By Peter W. PENG 2024.10.16

Editor's Note: As carbapenem-resistant Gram-negative bacteria (CRO) have become increasingly prevalent, the development and application of novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations have gained significant attention from researchers worldwide. A recent…

Insights from Dr. Khalil Ghanem on the Challenges and Future of Syphilis Diagnosis, Treatment, and Prevention

By Ren Jiamo 2024.10.15

Editor's Note: As the incidence of syphilis continues to rise, clinicians are faced with an increasing number of patients with complex clinical presentations, posing significant challenges in patient management. At…

Application of carbapenems in the treatment of MDR-GNB and management of drug resistance

By Mourabit Halima 2024.10.15

Editor's note: With the increase in multi-drug resistant Gram-negative bacterial infections (MDR-GNB) worldwide, the use strategy of carbapenems as key drugs for the treatment of such infections has received widespread…

AIDS Exclusive Interview | AMP Trial: Successes and Breakthroughs in HIV Prevention

By Peng Longmei 2024.10.14

Editor's Note: The breakthrough results from the Antibody Mediated Prevention (AMP) trials have revitalized global public health efforts in the field of HIV prevention. At the AIDS 2024 conference, Dr.…

AIDS Interview | HIV Vaccine: Where Are We Now, and What Does the Future Hold?

By Ren Jiamo 2024.10.14

Editor's Note: In the global fight against AIDS, the development of an HIV vaccine has always been a focal point of attention. Recently, Dr. Devin Sok, Vice President of the…

Dr. Hongzhou Lu: Driving High-Quality Development in Infectious Disease Prevention with Innovative Productivity at the 15th Tuberculosis Oriental Forum

By Peng Longmei 2024.10.12

Editor’s Note: Innovation is the primary driving force for development and a key component of new quality productivity that the nation is advocating. In medicine, particularly in preventing and treating…

Dr. Shuihua Lu: Expanding from Tuberculosis-Free Communities to Tuberculosis-Free Cities with the Power of Technology丨15th Tuberculosis Eastern Forum

By Mourabit Halima 2024.10.09

Editor's Note: The convergence of innovation and knowledge flows through Shenzhen, a city in the Greater Bay Area. The "2024 Annual Meeting of the National Clinical Research Center for Infectious…